IPSEY Ipsen SA Sponsored ADRs
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience and rare diseases. It operates through following segments: Specialty Care and Consumer Healthcare. The Specialty Care segment focuses on Oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and Rare Diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The Consumer Healthcare segment include brands such as Smecta, a naturally extracted purified clay for the symptomatic treatment of acute diarrhea; Tanakan, a standardized extract from the leaves of Ginkgo biloba for the treatment of various neurological and neuro-sens or ial disorders; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults and children; and Fortrans, a colon cleansing solution indicated for patients in preparation for endoscopic, radiological examinations or colonic surgery. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France. This is an ADR of a company whose stock trades outside of the U.S. as the symbol FP:IPN.
This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.
$28.11 Pink
As of 03/23/2023 OTCMarkets
Security Information
Category1: US Equity
Category2: ADRs
Category3: Mid cap
GICS sector: Health Care
Industry: Drug Manufacturers—Specialty &
Index country: France
Country of incorporation: France
IPO date: 06/08/2010
Outstanding shares: 335,258,104
Average volume: 538
Market cap: $9,424,105,303
Current dividend yield: 0.00%
Sedol:
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%